Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma

References

• Gandhi VD, Davidson C, Asaduzzaman M, et al. House dust mite interactions with airway epithelium: role in allergic airway inflammation. Curr Allergy Asthma Rep. 2013;13:262–270.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol. 2001;1:7–13.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Ciprandi G, Canonica GW. United airways disease: therapeutic aspects. Thorax. 2000;55 Suppl 2:S26–S27.
   Google Scholar
• Colloff MJ. Dust mites. Dordrecht: Springer; 2009.
   Google Scholar
• Sunyer J, Jarvis D, Pekkanen J, et al. Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study. J Allergy Clin Immunol. 2004;114:1033–1039.
   PubMed Web of Science ®Google Scholar
• Arbes SJ Jr., Gergen PJ, Elliott L, et al. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol. 2005;116:377–383.
   PubMed Web of Science ®Google Scholar
• Bousquet PJ, Chinn S, Janson C, et al. Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I. Allergy. 2007;62:301–309.
   PubMed Web of Science ®Google Scholar
• Platts-Mills TA, Ward GW Jr., Sporik R, et al. Epidemiology of the relationship between exposure to indoor allergens and asthma. Int Arch Allergy Appl Immunol. 1991;94:339–345.
   PubMedGoogle Scholar
• Linneberg A, Henrik Nielsen N, Frølund L, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002;57:1048–1052.
   PubMed Web of Science ®Google Scholar
• Holt PG, Rowe J, Kusel M, et al. Toward improved prediction of risk for atopy and asthma among preschoolers: a prospective cohort study. J Allergy Clin Immunol. 2010;125:653–659.
   PubMed Web of Science ®Google Scholar
• Lodge CJ, Lowe AJ, Gurrin LC, et al. House dust mite sensitization in toddlers predicts current wheeze at age 12 years. J Allergy Clin Immunol. 2011;128:782–788.
   PubMed Web of Science ®Google Scholar
• Lau S, Illi S, Sommerfeld C, et al. Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Multicentre Allergy Study Group. Lancet. 2000;356:1392–1397.
   PubMed Web of Science ®Google Scholar
• Illi S, Von ME, Lau S, et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet. 2006;368:763–770.
   PubMed Web of Science ®Google Scholar
• GINA Executive Committee. Global Initiative for Asthma; Global Strategy for Asthma Management and Prevention. Bethesda (MD): National Heart, Lung and Blood Institute, National Institute of Health; 2015.
   Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63 Suppl 86:8–160.
   PubMed Web of Science ®Google Scholar
• Calderón MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136:38–48.
   PubMed Web of Science ®Google Scholar
• Nurmatov U, Van Schayck CP, Hurwitz B, et al. House dust mite avoidance measures for perennial allergic rhinitis: an updated Cochrane systematic review. Allergy. 2012;67:158–165.
   PubMed Web of Science ®Google Scholar
• Terreehorst I, Duivenvoorden HJ, Tempels-Pavlica Z, et al. The effect of encasings on quality of life in adult house dust mite allergic patients with rhinitis, asthma and/or atopic dermatitis. Allergy. 2005;60:888–893.
   PubMed Web of Science ®Google Scholar
• Custovic A, Wijk RG. The effectiveness of measures to change the indoor environment in the treatment of allergic rhinitis and asthma: ARIA update (in collaboration with GA(2)LEN). Allergy. 2005;60:1112–1115.
   PubMed Web of Science ®Google Scholar
• Allam J-P, Novak N. Immunological mechanisms of sublingual immunotherapy. Curr Opin Allergy Clin Immunol. 2014;14:564–569.
   PubMed Web of Science ®Google Scholar
• Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2011;11:586–593.
   PubMed Web of Science ®Google Scholar
• Burks AW, Calderon MA, Casale T, et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288–1296.
   PubMed Web of Science ®Google Scholar
• Scadding G, Durham S. Mechanisms of sublingual immunotherapy. J Asthma. 2009;46:322–334.
   PubMed Web of Science ®Google Scholar
• Calderón MA, Simons FE, Malling H-J, et al. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy. 2012;67:302–311.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: World Allergy Organization position paper 2009. World Allergy Organ J. 2009;2:233–281.
   PubMedGoogle Scholar
• Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol. 2013;131:1361–1366.
   PubMed Web of Science ®Google Scholar
• Alvarez-Cuesta E, Bousquet J, Canonica GW, et al. Standards for practical allergen-specific immunotherapy. Allergy. 2006;61 Suppl 82:1–20.
   PubMed Web of Science ®Google Scholar
• Mauro M, Boni E, Makri E, et al. Pharmacodynamic and pharmacokinetic evaluation of house dust mite sublingually administered immunotherapy tablet in the treatment of asthma. Expert Opin Drug Metab Toxicol. 2015;11:1937–1943.
   PubMed Web of Science ®Google Scholar
• ALK-Abelló A/S. Acarizax summary of product characteristics. 2015. Available from: http://mri.medagencies.org/download/DE_H_1947_001_FinalSPC.pdf.
   Google Scholar
• Bergmann K, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mites allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133:1608–1614.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Pasquali M, Ariano R, et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy. 2006;61:849–854.
   PubMed Web of Science ®Google Scholar
• Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet. 1998;351:629–632.
   PubMed Web of Science ®Google Scholar
• Henmar H, Frisenette SM, Grosch K, et al. Fractionation of source materials leads to a high reproducibility of the SQ house dust mite SLIT-tablets. Int Arch Allergy Immunol. 2016;169:23–32.
   PubMed Web of Science ®Google Scholar
• Seager H. Drug-delivery products and the zydis fast-dissolving dosage form. J Pharm Pharmacol. 1998;50:375–382.
   PubMed Web of Science ®Google Scholar
• Badgujar BP, Mundada AS. The technologies used for developing orally disintegrating tablets: a review. Acta Pharm. 2011;61:117–139.
   PubMed Web of Science ®Google Scholar
• EMEA. Committee for Medicinal Products for Human Use (CHMP) and Efficacy Working Party (EWP): Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases; EMEA/CHMP/EWP/18504/2006. 2008.
   Google Scholar
• Bagnasco M, Altrinetti V, Pesce G, et al. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol. 2005;138:197–202.
   PubMed Web of Science ®Google Scholar
• Bagnasco M, Mariani G, Passalacqua G, et al. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol. 1997;100:122–129.
   PubMed Web of Science ®Google Scholar
• Novak N, Allam J-P. Mucosal dendritic cells in allergy and immunotherapy. Allergy. 2011;66 Suppl 95:22–24.
   PubMed Web of Science ®Google Scholar
• Novak N, Bieber T, Allam J-P. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy. 2011;66:733–739.
   PubMed Web of Science ®Google Scholar
• Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011;127:18–27.
   PubMed Web of Science ®Google Scholar
• Gleich GJ, Zimmermann EM, Henderson LL, et al. Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol. 1982;70:261–271.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Braquemond P, Feinberg J, et al. Specific IgE response before and after rush immunotherapy with a standardized allergen or allergoid in grass pollen allergy. Ann Allergy. 1986;56:456–459.
   PubMedGoogle Scholar
• Van RR, Van Leeuwen WA, Dieges PH, et al. Measurement of IgE antibodies against purified grass pollen allergens (Lol p 1, 2, 3 and 5) during immunotherapy. Clin Exp Allergy. 1997;27:68–74.
   PubMed Web of Science ®Google Scholar
• Flicker S, Valenta R. Renaissance of the blocking antibody concept in type I allergy. Int Arch Allergy Immunol. 2003;132:13–24.
   PubMed Web of Science ®Google Scholar
• Wachholz PA, Durham SR. Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol. 2004;4:313–318.
   PubMed Web of Science ®Google Scholar
• Scadding GW, Shamji MH, Jacobson MR, et al. Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3-expressing cells and elevated allergen-specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E-facilitated allergen binding to B cells. Clin Exp Allergy. 2010;40:598–606.
   PubMed Web of Science ®Google Scholar
• Shamji MH, Ljørring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012;67:217–226.
   PubMed Web of Science ®Google Scholar
• Corzo JL, Carrillo T, Pedemonte C, et al. Tolerability during double-blinded randomised phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. J Investig Allergol Clin Immunol. 2014;24:154–161.
   PubMed Web of Science ®Google Scholar
• Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015;135:1494–1501.
   PubMed Web of Science ®Google Scholar
• Klimek L, Mosbech H, Zieglmayer P, et al. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis. Expert Rev Clin Immunol. 2016;12:369–377.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Deckelmann R, De Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: A randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134:568–575.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. JAMA. 2016;315:1715–1725.
   PubMed Web of Science ®Google Scholar
• De Blay F, Kuna P, Prieto L, et al. SQ HDM SLIT-tablet (ALK) in treatment of asthma - post hoc results from a randomised trial. Respir Med. 2014;108:1430–1437.
   PubMed Web of Science ®Google Scholar
• Nolte H, Maloney J, Nelson HS, et al. Effect of 12 SQ house dust mite sublingual immunotherapy tablet on asthma symptoms using an environmental exposure chamber. Ann Allergy Asthma Immunol. 2015;115:A112.
   Google Scholar
• Bateman ED, Reddel HK, Eriksson G, et al. Overall asthma control: the relationship between current control and future risk. J Allergy Clin Immunol. 2010;125:600–608.
   PubMed Web of Science ®Google Scholar
• Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112:146–153.
   PubMed Web of Science ®Google Scholar
• Nolte H, Amar N, Bernstein DI, et al. Safety and tolerability of a short ragweed sublingual immunotherapy tablet. Ann Allergy Asthma Immunol. 2014;113:93–100.
   PubMed Web of Science ®Google Scholar
• Didier A, Worm M, Horak F, et al. Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen-induced rhinoconjunctivitis. J Allergy Clin Immunol. 2011;128:559–566.
   PubMed Web of Science ®Google Scholar
• Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2015. doi:10.1016/j.jaci.2015.06.036.
   Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717–725.
   PubMed Web of Science ®Google Scholar
• Brozek JL, Bousquet J, Baena-Cagnani CE, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126:466–476.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: world allergy organization position paper 2013 update. World Allergy Organ J. 2014;7:6.
   PubMedGoogle Scholar